Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology, and cardiology, today announced an exclusive licensing agreement with the University of Sydney for a microtubule-targeting agent to treat brain cancers.
The therapeutic candidate, LBS-002, is a small molecule that disrupts the division of cancer cells by preventing the formation of microtubules (the cell structures responsible for the segregation of chromosomes in cell division).
LBS-002's ability to cross the blood-brain barrier shows promise for treating both primary and metastatic brain cancers
"To date, treating primary glioblastomas and metastatic brain cancers has been challenging because the blood-brain barrier prevents effective drugs from reaching their targets," stated Dr. Tom Lin, CEO of Lin Bioscience. "LBS-002's ability to cross the blood-brain barrier enables it to overcome the permeability limitations experienced by traditional treatments, making it a promising therapeutic candidate. We're excited to work with the expertise of Dr. Munoz, Dr. Kassiou and their teams at the University of Sydney to bring new cancer therapies to the clinic."
Under the terms of the agreement, Lin BioScience will gain exclusive global rights to the development and commercialization of intellectual property developed at University of Sydney by Drs. Lenka Munoz and Michael Kassiou. Further terms of the agreement are not disclosed.
"Our research has passed the discovery stage and now our goal is to progress into clinical testing," stated Drs. Munoz and Kassiou. "LBS-002 provides an exciting basis for a program that will lead to new treatments for brain tumors and we are very excited to be working with an innovative biotech like Lin BioScience in translating our fundamental research into clinical studies," said Drs. Munoz and Kassiou.
About Lin BioScience
Lin BioScience is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Lin BioScience's diverse and novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, and cardiology.